Veradermics Files for IPO Amid Rising Net Losses
Veradermics, a clinical-stage dermatology firm, has filed for a U.S. IPO, planning to list on the NYSE under the ticker MANE. The filing follows a reported net loss of $55.2 million for the nine months ending September 2025, compared to $20.8 million the previous year.
Insights:
Veradermics Inc. , a clinical-stage dermatology company based in New Haven, Connecticut, has filed for an initial public offering (IPO) in the United States. Announced on January 9, 2026, the company plans to list on the New York Stock Exchange under the ticker symbol MANE. This move comes as Veradermics reported a significant widening of its net losses, recording $55.2 million for the nine months ending September 30, 2025, compared to $20.8 million during the same period in the previous year.
The company is developing VDPHL01, an oral non-hormonal candidate aimed at treating pattern hair loss, a niche within the dermatological sector. Veradermics is currently in the clinical stage and has yet to generate revenue, underscoring the financial challenges it faces as it seeks public funding. The IPO is being underwritten by Jefferies Financial Group Inc. , Citigroup Inc. , and Leerink Partners.
